Login

Journal Image
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
ISSN (Print): 1872-2148
ISSN (Online): 2212-3334
VOLUME: 3
ISSUE: 3
DOI: 10.2174/187221409789104755









Update on ICOS: A Possible Target for Turning-Off Autoimmunity

img
Author(s): Priya Sakthivel
Pages 205-213 (9)
Abstract:
Inducible Co-stimulator (ICOS) is one of the co-stimulatory molecules that are unregulated within hours after TCR engagement. The interaction between ICOS and its ligand ICOSL positively co-stimulates T cell activation and proliferation. Thus, ICOS/ICOSL pathway contributes to one of the predisposing factors for autoimmune condition. Therefore, the positive co-stimulatory properties of ICOS are now being regarded as a possible and potential target for treating autoimmune disorders. Several in vivo studies have confirmed the amelioration of autoimmune disease by targeting ICOS pathway. This mini-review comprehensively describes the updated issues regarding ICOS from their discovery and functional consequences (at both genetic and protein aspects) to the recent patents in targeting ICOS pathway for turning-off immune responses in autoimmunity.
Keywords:
ICOS, ICOSL (B7RP-1), co-stimulatory molecules, autoimmune disease
Affiliation:
Rheumatology Unit, Center for Molecular medicine (L8:04), Karolinska Institutet, 17176 Stockholm, Sweden.